 siRNA Expression Vectors
GenScript provides a complete set of vectors for the expression of siRNA. These vectors use U6 (regular or enhanced), H1 (regular, inducible or enhanced) or CMV promoter to drive the siRNA expression. Each vector carries a neomycin, hygromycin, zeomycin or puromycin resistance gene as the selectable marker, which can be used for establishing stable cell lines. Some of the vectors carry a coral GFP (cGFP) marker for tracking transfection efficiency. To complete its siRNA set, Gencript also provides viral-based (Lenti, Retro, Adeno) siRNA vectors for more effective delivery of siRNA into almost any mammalian cell, including non-dividing cells and whole model organisms
GenScript also
provides a pool of vector primers for your convenience. With GenScript's innovative technology and committed support, you have a
partnership for success. Read on and click the following
links for more information on our vector protocols,
restriction enzyme maps, vector maps, sequences, and price
details.
- Expression Vectors
- siRNA Controls
- Vector Primers
Plasmid siRNA Expression Vectors
These vectors are designed for mammalian transfection. They each carry a neomycin, hygromycin, or zeomycin resistance gene as a selectable marker, which can be used for establishing stable cell lines. The pRNAT vectors also carry a GFP marker (coral GFP or cGFP) under CMV promoter * control, which can be used to track transfection efficiency. They use regular or enhanced U6, or H1, or CMV promoters to drive siRNA expression. |
Inducible siRNA Expression Vectors
The H1.2 promoter is an engineered inducible promoter ** containing a tetracycline operator (TetO1). The tetracycline operator itself has no effect on expression. When the tetracycline repressor (TetR) is present, it effectively binds the TetO1 and blocks the transcription. In the presence of tetracycline or doxycycline, the inducer binds TetR, causing the TetR protein to release the TetO1 site, and depress transcription. |
Viral siRNA Vectors
The H1.2 promoter is an engineered inducible promoter ** containing a tetracycline operator (TetO1). The tetracycline operator itself has no effect on expression. When the tetracycline repressor (TetR) is present, it effectively binds the TetO1 and blocks the transcription. In the presence of tetracycline or doxycycline, the inducer binds TetR, causing the TetR protein to release the TetO1 site, and depress transcription. |
|
* Limited
Use Label License: The use of CMV promoter is covered under U.
S. Patents Nos. 5,168,062 and 5,385,839, owned and licensed by
the University of Iowa Research Foundation and is sold for
research use only. Commercial users must obtain a license to
these patents directly from the University of Iowa Research
Foundation (UIRF), 214 Technology Innovation Center, Iowa
City, Iowa 52242. For further information, please contact the
Associate Director of UIRF at 319-335-4546.
** Limited Use Label License: This H1.2 inducible promoter is covered by United States Patent Applications Nos. 60,505,677, owned by GenScript USA Inc.. The purchase of this product conveys to the buyer the limited, non-exclusive, non-transferable right (without the right to resell, repackage, or further sublicense) under these patent rights to perform the siRNA synthesis methods claimed in the patent application for research and development purposes solely in conjunction with this product.
Positive Controls:
siRNA positive controls are useful as a means of checking experimental systems.
That is, when the expected results appear with a positive control siRNA,
one may be reasonably sure that the transfections, the RNA
extraction, and the assay, are reliable and robust.
A good positive control reagent targets a well-expressed but non-essential
gene. Such controls are useful for establishing experimental parameters without affecting cellular
viability. Some positive controls can also be used as negative controls. Ordering Information
Negative Controls:
A non-targeting siRNA control helps to determine whether or not any decrease in gene expression levels observed with a gene-specific siRNA is related to a sequence-specific RNAi event. Global down-regulation may be due to cellular stress responses to a certain transfection reagent or technique. Without negative controls, a researcher might mistakenly interpret this broad, non-specific silencing as true gene-specific silencing. Negative siRNA control reagents are designed to have no known target in the cell line of choice. These reagents allow researchers to distinguish sequence-specific silencing from sequence-independent effects. Such sequence-independent effects can include toxicity resulting from the process of transfection in conjunction with nucleic acid delivery or hypersensitivity to the introduction of double-stranded RNA. Investigators are encouraged to test multiple candidates in their own experimental systems to empirically confirm that the negative controls do not result in any observable and unintended off-target effects.
Ordering Information
|
